Beyond PD-L1: Taking away TIM3 and Tregs stops cancer regrowth after immunotherapy

CU Cancer Center study presented at AACR18 shows that TIM3 and/or increased regulatory T cells (Tregs) within a tumor may help cancers inactivate immune system killer T cells that would otherwise identify and attack the cancer.

Is whole-brain radiation still required for all brain metastases from small-cell lung cancer?

“We hope that this analysis will encourage other investigators to ask questions about the potential role of SRS for carefully-selected patients with small-cell lung cancer,” says Chad Rusthoven, MD.

AACR: How do melanoma cells survive drug treatment long enough to acquire drug resistance?

“What we’re looking at here is the immediate response of melanoma cells to BRAF inhibitor treatment, in real time, over the first few days of treatment. Not genetic changes, but the mechanisms the cell uses to evade treatment and start dividing again in a matter of a few days,” says Sabrina Spencer, PhD.

Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers

CU Cancer Center studies provide in-depth look at how ALK+ and ROS1+ cancers evolve to resist treatment.

Mental Health and Cancer

“Cancer doesn’t just affect you physically,” says Elissa Kolva, PhD, University of Colorado Cancer Center researcher. “It can affect every aspect of your life including your role in your family, your relationships, your work life, and even your identity.”

Latest News from the University of Colorado Cancer Center

@CUCancerCenter on Twitter